Compare ADMA Biologics Inc (ADMA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Starbucks Corp — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Starbucks Corp trades at $106.93 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 54.8× ADMA Biologics Inc's market cap, and Starbucks Corp pays a 2.33% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SBUX | |
|---|---|---|
Market Cap | $2.22B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $108.37 |
52-Week Low | $7.60 | $78.46 |
Enterprise Value | $2.29B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Starbucks (SBUX) trades at $104.65, down 0.88% on the day, with technical indicators neutral and support near $104. The company reported mixed quarterly EPS results, beating in Q1 and Q2 2026 but missing in Q4 2025, while raising its fiscal 2026 outlook. Revenue grew to $37.18B in 2025, but net income fell to $1.86B, compressing margins. Analyst consensus is a Buy with a $113.60 price target, citing a traffic recovery and cost initiatives.
The outlook hinges on sustaining sales momentum and margin expansion amid high valuation multiples. Risks include execution on turnaround plans, competitive pressure, and debt levels. Upside potential exists if earnings recovery continues, but investors face volatility from macroeconomic headwinds and premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
